Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Pelthos Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Pelthos Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 78.6%. For fiscal 2025 it was 76.3%.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 76.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 76.9% | – |
| Q1 FY2026 | Mar 31, 2026 | 84.7% | – |
| Q4 FY2025 | Dec 31, 2025 | 82.2% | – |
| Q3 FY2025 | Sep 30, 2025 | 68.7% | – |
See a number that looks wrong?